Louisiana State Employees Retirement System Buys Shares of 29,700 Integra LifeSciences Holdings Corporation $IART

Louisiana State Employees Retirement System bought a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 1st quarter, HoldingsChannel reports. The firm bought 29,700 shares of the life sciences company’s stock, valued at approximately $280,000.

Other hedge funds also recently made changes to their positions in the company. Global Retirement Partners LLC bought a new stake in shares of Integra LifeSciences during the 4th quarter valued at $25,000. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares in the last quarter. GAMMA Investing LLC lifted its stake in Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Integra LifeSciences in the fourth quarter worth $124,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Thursday, June 18th. Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Citigroup reiterated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday. Finally, Wells Fargo & Company boosted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences has an average rating of “Reduce” and a consensus target price of $17.17.

Integra LifeSciences Trading Up 6.3%

Shares of IART stock opened at $18.39 on Friday. The business has a 50-day moving average price of $16.15 and a two-hundred day moving average price of $12.81. Integra LifeSciences Holdings Corporation has a 12-month low of $8.70 and a 12-month high of $18.92. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The firm has a market cap of $1.43 billion, a P/E ratio of -2.85, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.